No Data
Huachuang Securities: In the first quarter, the issuance of vaccine batches increased significantly, and the price of macrocyclic lactone veterinary medicine Active Pharmaceutical Ingredients continues to rise.
The demand for animal health products is gradually recovering, and by 2025, the breeding sector is expected to maintain profitability. The continuity of demand for animal health products may be ensured, and the Operation in the animal health Sector is gradually establishing a turning point.
Tianjin Ringpu Bio-Technology (300119.SZ): Obtained approval number for veterinary drug products.
Gelonghui, April 16 - Tianjin Ringpu Bio-Technology (300119.SZ) announced that its wholly-owned subsidiary, Ringpu (Tianjin) Biopharmaceutical Co., Ltd., has passed the national comparison number evaluation review for its cat deworming drug and has recently obtained the veterinary drug product approval number issued by the Ministry of Agriculture and Rural Affairs. Milbemycin oxime and praziquantel tablets (for cats) is a broad-spectrum, highly effective compound internal parasitic drug that can simultaneously kill various common parasites in pet cats, such as tapeworms, roundworms, and hookworms. It has four core advantages: broad-spectrum deworming, safety and reliability, convenience and ease of use, and long-lasting protection. This product relies on the company's cutting-edge R&D platform and strictly adheres to veterinary drug R&D regulations.
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Tianjin Ringpu Bio-Technology (300119.SZ): In 2024, the gross margin of the pet supply chain is 14.99%, which is an increase of 0.89% compared to the same period last year.
On April 3rd, Glonghui reported that Tianjin Ringpu Bio-Technology (300119.SZ) stated in a recent investor relations activity that the gross margin for the company's veterinary Pharmaceutical and vaccine Business will remain stable in 2024. The company acquired control of Zhongrui Supply Chain under the same control in 2024, with a gross margin of 14.99% for the pet supply chain in 2024, an increase of 0.89% compared to the same period last year. However, this is relatively low compared to the gross margin level of the original Business, leading to a structural decrease in the overall gross margin.
Tianjin Ringpu Bio-Technology (300119.SZ): In 2024, over 20 group clients have reached cooperation agreements worth tens of millions.
On April 3rd, Gelonghui reported that Tianjin Ringpu Bio-Technology (300119.SZ) recently stated during an investor relations event that the company has targeted the top 300 poultry, top 100 livestock, top 30 aquatic, and top 30 ruminant breeding groups and large-scale farms. It has established strategic partnerships with several leading breeding groups, transitioning from the supply chain to the industrial ecological chain, and building a community of shared interests. In 2024, it has reached cooperation agreements worth tens of millions with more than 20 group clients; deeply exploring customer needs, it has successfully developed over 50 products each worth tens of millions.
Tianjin Ringpu Bio-Technology (300119.SZ): This year, it will promote the launch of oral pet dewormers and a series of pet health products.
On April 3rd, Gelonghui reported that Tianjin Ringpu Bio-Technology (300119.SZ) recently stated in an investor relations activity that in the pet Sector, the focus on the Biological Products side is on advancing the development of products such as the feline trivalent live vaccine, feline quadrivalent vaccine, feline interferon, canine quadrivalent vaccine, and feline infectious peritonitis vaccine. On the Pharmaceutical side, the emphasis is on antiparasitic drugs, with plans to promote the market launch of oral formulations of pet antiparasitic drugs and a series of pet health products this year.
Earnings Working Against Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Share Price
